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A B S T R A C T
Background
Selective type 1 cannabinoid (CB1) receptor antagonists may assist with smoking cessation by restoring the balance of the endocannabi-
noid system, which can be disrupted by prolonged use of nicotine. They also seek to address many smokers’ reluctance to persist with
a quit attempt because of concerns about weight gain.
Objectives
To determine whether selective CB1 receptor antagonists (currently rimonabant and taranabant) increase the numbers of people
stopping smoking
To assess their effects on weight change in successful quitters and in those who try to quit but fail.
Search methods
We searched the Cochrane Tobacco Addiction Review Group specialized register for trials, using the terms (’rimonabant’ or ’taranabant’)
and ’smoking’ in the title or abstract, or as keywords. We also searched MEDLINE, EMBASE, CINAHL and PsycINFO, using major
MESH terms. We acquired electronic or paper copies of posters of preliminary trial results presented at the American Thoracic Society
Meeting in 2005, and at the Society for Research on Nicotine and Tobacco European Meeting 2006. We also attempted to contact the
authors of ongoing studies of rimonabant, and Sanofi Aventis (manufacturers of rimonabant). The most recent search was in January
2011.
Selection criteria
Types of studies
Randomized controlled trials
Types of participants
Adult smokers
Types of interventions
Selective CB1 receptor antagonists, such as rimonabant and taranabant.
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Types of outcome measures
The primary outcome is smoking status at a minimum of six months after the start of treatment. We preferred sustained cessation rates
to point prevalence, and biochemically verified cessation to self-reported quitting. We regarded smokers who drop out or are lost to
follow up as continuing smokers. We have noted any adverse effects of treatment.
A secondary outcome is weight change associated with the cessation attempt.
Data collection and analysis
Two authors checked the abstracts for relevance, and attempted to acquire full trial reports. One author extracted the data, and a second
author checked them.
Main results
We found three trials which met our inclusion criteria, covering 1567 smokers (cessation: STRATUS-EU and STRATUS-US), and
1661 quitters (relapse prevention: STRATUS-WW). At one year, the pooled risk ratio (RR) for quitting with rimonabant 20 mg was
1.50 (95% confidence interval (CI) 1.10 to 2.05). No significant benefit was demonstrated for rimonabant at 5 mg dosage. Adverse
events included nausea and upper respiratory tract infections.
In the relapse prevention trial, smokers who had quit on the 20 mg regimen were more likely to remain abstinent on either active
regimen than on placebo; the RR for the 20 mg maintenance group was 1.29 (95% CI 1.06 to 1.57), and for the 5 mg maintenance
group 1.30 (95% CI 1.06 to 1.59). There appeared to be no significant benefit of maintenance treatment for the 5 mg quitters.
One trial of taranabant was not included in our meta-analyses, as it followed participants only until end of treatment; at eight weeks it
found no benefit for treatment over placebo, with an OR of 1.2 (90% CI 0.6 to 2.5).
For rimonabant, weight gain was reported to be significantly lower among the 20 mg quitters than in the 5 mg or placebo quitters.
During treatment, overweight or obese smokers tended to lose weight, while normal weight smokers did not. For taranabant, weight
gain was significantly lower for 2-8 mg versus placebo at the end of eight weeks of treatment.
In 2008, post-marketing surveillance led the European Medicines Agency (EMEA) to require Sanofi Aventis to withdraw rimonabant,
because of links to mental disorders. The development of taranabant was also suspended by Merck & Co because of unacceptable
adverse events.
Authors’ conclusions
From the trial reports available, rimonabant 20 mg may increase the chances of quitting approximately 1½-fold. The evidence for
rimonabant in maintaining abstinence is inconclusive.
Rimonabant 20 mg may moderate weight gain in the long term. Taranabant 2-8 mg may moderate weight gain, at least in the short
term.
In 2008, development of both rimonabant and taranabant was discontinued by the manufacturers.
P L A I N L A N G U A G E S U M M A R Y
Can cannabinoid type 1 receptor antagonists help smokers to quit, and could they also reduce the amount of weight gained
during the quitting process?
Long-term use of nicotine can upset the endocannabinoid system in the brain, which controls food intake and energy balance.
Rimonabant and similar drugs may help smokers to quit by rebalancing the system, which then reduces nicotine and food cravings.
We searched our own specialised register of controlled trials. We also contacted Sanofi Aventis, the manufacturers of rimonabant,
and researchers who presented early findings at conferences. We found two randomized controlled trials (RCTs) of rimonabant for
smoking cessation, covering 1567 smokers, and one RCT of rimonabant for relapse prevention covering 1661 quitters. The available
information shows that rimonabant at the 20 mg dose increased by 1½-fold the chances of not smoking at one year, compared with
placebo. Rimonabant 5 mg did no better than placebo at any time point. In the relapse prevention trial, smokers who quit successfully
with rimonabant 20 mg were 1½ times more likely to remain abstinent on active treatment (5 mg or 20 mg for 42 weeks) than on
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placebo. For those who quit successfully on 5 mg, neither active nor placebo treatment appeared to benefit them in avoiding relapse.
This inconsistent picture makes it difficult to find a clear benefit for rimonabant in preventing relapse. One trial of taranabant (317
smokers) did not find a benefit for treatment over placebo, and the taranabant group suffered more side effects than the placebo group.
Main side effects for rimonabant included nausea and upper respiratory tract infections, and serious harms were reported to be low.
For taranabant, the main side effects included problems with digestive, nervous, psychiatric, skin and blood vessel organ systems. For
both drugs, the number and severity of the side effects increased in those taking higher doses. Although the evidence on weight change
is sparse in these trials, weight gain was reported to be significantly lower among the rimonabant 20 mg quitters than in the 5 mg or
placebo quitters. During treatment, overweight or obese smokers tended to lose weight on 20 mg, while normal weight smokers did
not. Taranabant also limited weight gain during cessation attempts. In 2008 both rimonabant and taranabant were withdrawn by the
manufacturers, because of links to mental disorders and unacceptable side effects.
B A C K G R O U N D
About 70% of smokers want to quit, with the majority citing con-
cerns about their health as a primary reason for giving up smok-
ing (ONS 2002). There is widespread concern among smokers,
however, about the risks of gaining weight after quitting. In the
USA it is estimated that 75% of smokers gain weight when they
stop smoking (USPHS 1990), with the majority of the weight
gain in the first year of smoking abstinence (O’Hara 1998). Men
who sustain abstinence have been shown to gain an average of
4.9 kilograms in the first year of abstinence, and women 5.2 kilo-
grams, with further gains of 2.7 kilograms and 3.5 kilograms re-
spectively across the following four years of abstinence (O’Hara
1998).Other evidence suggests that in the longer term ex-smokers’
weight may return to the comparable weight of someone who has
never smoked (Mizoue 1998). While some studies have suggested
that nicotine replacement therapy or bupropion may moderate
post-cessation weight gain (Filozof 2004), no pharmacotherapies
are yet available that target both smoking cessation and weight
control simultaneously.
The central cannabinoid (CB1) receptors have recently been im-
plicated in brain reward function, and are thought to have a role
in controlling food consumption and in dependence and habit-
uation. Excessive eating and fat accumulation are associated with
over-activation of the endocannabinoid system, which is involved
in the regulation of food intake and energy expenditure. Repeated
nicotine use may also overstimulate the endocannabinoid system.
It is thought that rimonabant may work by selectively blocking
the CB1 receptors,thereby restoring the balance and inhibiting
nicotine and food cravings.
Rimonabant (SR 141716; trade name Acomplia) was the first se-
lective cannabinoid type 1 receptor antagonist to be produced and
clinically tested. It was developed initially as a possible treatment
for obesity, but it was subsequently proposed as an aid to smoking
cessation, with the potential to protect successful quitters from
significant post-cessation weight gain (ACC 2004; Sanofi-Synth
2004). The development and testing of rimonabant was of par-
ticular interest to clinicians, as it appeared to offer an effective
and simultaneous treatment for the two major cardiac risk fac-
tors of obesity and smoking (Fagerström 2006; Gelfand 2006; Le
Foll 2008). Moreover, smoking cessation is itself associated with
weight gain. Rimonabant therefore also addressed many smokers’
reluctance to persist with a quit attempt because of concerns over
weight gain (Pomerleau 2000). The beneficial effects of rimona-
bant on weight loss have been demonstrated in a recent Cochrane
review (Curioni 2006).
Rimonabant 20 mg dose was licensed as an aid for weight control
in the European Union in June 2006, but was not licensed for
smoking cessation. It has not been approved by the FDA for sale
in the USA. The Summary of Product Characteristics (Acomplia
SPC 2006) advises against its use by those with severe hepatic
or renal impairment, severe psychiatric illness or lactose intoler-
ance, and advises caution in its use by the elderly, by patients with
epilepsy or by those on antidepressant treatment. It is also contra-
indicated during pregnancy or while breast-feeding. Reports of
raised levels of depression and suicidal thoughts led in October
2008 to the withdrawal of rimonabant as a prescription drug in
European countries (see Results section).
Phase III trials were conducted to test the use of rimonabant for
long-term smoking cessation with the avoidance of significant
weight gain. The STRATUS program (STudies with Rimonabant
And Tobacco USe), produced conference reports of two cessa-
tion trials (STRATUS-EU 2006 and STRATUS-US 2006), and
reported intermediate outcomes for a two-year relapse prevention
trial (STRATUS-WW 2005).
Another CB1 receptor antagonist, taranabant, has been developed
by the US drug major Merck & Co (Fremming 2008). Although
primarily targeting obesity, it was also tested as an aid to smoking
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cessation. Because the trial lasted only eight weeks, we have not
included it in our review findings, but we report the findings for
weight gain, and the adverse events profile is considered in the
Discussion section. Because of the neuropsychiatric side effects,
the development of taranabant for any conditionwas discontinued
in October 2008.
O B J E C T I V E S
1. To determine whether selective CB1 receptor antagonists in-
crease the numbers of people stopping smoking.
2. To assess their effects on weight change in successful quitters
and in those who try to quit but fail.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials
Types of participants
Adult smokers
Types of interventions
Selective CB1 receptor antagonists, such as rimonabant and taran-
abant, and any other drugs of this class as they reach Phase II or
Phase III trial stage. The drugs may be used alone or in combina-
tion with behavioural therapies or other pharmacotherapies.
Types of outcome measures
The primary outcome is smoking status at a minimum of six
months after the start of treatment. Trials with shorter follow
up have not been included in the meta-analysis. We have used
sustained cessation rates in preference to point prevalence; sus-
tained cessation refers either to complete abstinence (continuous)
or to prolonged abstinence (complete abstinence following a post-
quit two-week period of grace in which minor relapse may occur)
(Hughes 2003). We prefer biochemically verified cessation to self-
reported quitting. The strictest definition of smoking cessation
reported was used in the meta-analysis. Types of abstinence (con-
tinuous, prolonged, point prevalence) and levels of verification
(biochemical, self-report) have been considered as potential mod-
erators of outcome. We regard smokers who drop out or are lost
to follow up as continuing smokers. We have noted any adverse
effects of treatment.
A secondary outcome is change inweight associatedwith the cessa-
tion attempt.We have assessed change in baseline weight at longest
follow up (currently one year), and at the end of pharmacotherapy.
We have considered weight change in the subgroup of successful
quitters, in all those who were randomized, in the subgroup of
those who have failed to quit, according to weight classification
at baseline, and in the total sample, testing the sensitivity of the
results to different ways of handling missing data.
The possible findings include:
(i) Selective CB1 receptor antagonists may increase smoking ab-
stinence rates relative to a control or non-intervention group, and
there may be a significantly larger average weight gain in the in-
tervention than in the control group. Interpretation: The weight
gain in the intervention group would most probably be due to the
higher number of quitters in this group and there would be no
evidence to suggest that the intervention has reduced weight gain.
(ii) Selective CB1 receptor antagonists may increase quit rates rel-
ative to a control or non-intervention group, but without a signif-
icant difference in average weight gain between the groups. Inter-
pretation: This result would be difficult to interpret. It is possible
that the intervention may have counteracted some of the antici-
pated weight gain among the quitters. However, it is also possible
that there was a similar weight gain in quitters and continuing
smokers independently of the effects of the intervention.
(iii) Selective CB1 receptor antagonists may increase quit rates
relative to a control or non-intervention group, and there may
be a significantly smaller average weight gain in the intervention
group than in the control group. Interpretation: This would be
good evidence to suggest that the intervention has reduced weight
gain.
(iv) There may be no difference in quit rates between the selective
CB1 receptor antagonists group and the control group, but a sig-
nificantly smaller average weight gain in the intervention group
than in the control group. Interpretation: This would be evidence
for selective CB1 receptor antagonists counteracting weight gain.
Since selectiveCB1 receptor antagonistsmay have beneficial effects
on other risk factors for the development of cardiovascular disease
(Cleland 2004) these outcomes have also been considered.
Search methods for identification of studies
We searched the Cochrane Tobacco Addiction Review Group spe-
cialized register for trials, using the terms (’rimonabant’ or ’taran-
abant’) and ’smoking’ in the title or abstract, or as keywords.
This register has been developed from electronic searching of
MEDLINE, EMBASE, Science Citation Index and PsycINFO,
together with handsearching of specialist journals, conference pro-
ceedings and reference lists of previous trials and overviews. We
have also searched MEDLINE, EMBASE, and PsycINFO, us-
ing the major MESH terms (Endocannabinoids-physiology, Re-
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ceptors,-cannabinoid-agonists or Receptors,-cannabinoid-antago-
nists-and-inhibitors) or equivalent for other databases, combined
with MeSH or free text smoking-related terms (smok* or tobacco
or cigar* or nicotine). We have acquired electronic and/or paper
copies of posters of preliminary trial results presented at the Amer-
ican Thoracic Society Meeting in 2005, and at the Society for
Research on Nicotine and Tobacco European Meeting 2006. We
have also attempted to contact the authors of studies of rimona-
bant, and Sanofi Aventis (manufacturers of rimonabant).
The most recent search was in January 2011.
Data collection and analysis
Two authors checked the abstracts of studies generated by the
search strategy for relevance, and attempted to acquire full reports
of any trials that might be included in the review, but with only
limited success.One author extracted the data, and a second author
checked them. Any discrepancies were resolved bymutual consent,
or by recourse to the editorial base. We have noted reasons for the
non-inclusion of studies.
DATA EXTRACTION
The following information, where it was available for each trial, is
reported in the Table ’Characteristics of Included Studies’:
• Country and setting (e.g. primary care, community,
hospital outpatient/inpatient). no change
• Method of selection of participants (e.g. willingness to
make a quit attempt).
• Definition of smoker used.
• Method of randomization, and blinding of trialists,
participants and assessors.
• Demographic characteristics of participants (e.g. average
age, sex, average cigs/day).
• Intervention and control description (provider, length of
treatment, number of visits, etc.).
• Outcomes including definition of abstinence used, and
biochemical validation of cessation.
• Proportion of participants with follow-up data.
• Any adverse events.
• Secondary outcomes, including weight changes during and
after cessation, and other outcomes relevant to cardiovascular
risk, including lipid levels.
EVALUATION OF QUALITY
We evaluated the studies on the basis of the quality of the random-
ization and allocation concealment procedure used, as described
in the Cochrane Handbook. Studies are scored A if a method of
randomization and allocation concealment are reported that min-
imize the chance of selection bias. If insufficient information is
available they are scored B, and studies where allocation was not
concealed at the point of enrolment are scored C.
We calculated quit rates based on the numbers of patients random-
ized to an intervention, and excluding any deaths. We have used
an intention-to-treat (ITT) analysis, i.e. including all randomized
participants in the groups to which they were originally assigned.
We have regarded those who drop out or are lost to follow up as
continuing smokers. We have noted any deaths and adverse events
in the Results section.
WEIGHT CHANGE
For assessing the impact on weight change we have considered the
following outcomes where reported:
• Mean change in weight from baseline (pre-cessation) for
confirmed quitters. Since quitting is likely to be associated with
weight gain, an examination of the subgroup of successful
quitters will provide the most sensitive test of the impact of
selective CB1 receptor antagonists on weight gain.
• Mean weight change from baseline in point prevalence
quitters compared with quitters with continuous or prolonged
abstinence.
• Mean change in weight from baseline for those failing to
quit smoking. This outcome allows an assessment of whether
selective CB1 receptor antagonists affect changes in weight
among those who relapse or who continue to smoke.
• Mean change in weight from baseline for those completing
the study.
• Mean change in weight for those sub-groups who are
classed as obese, overweight or normal weight at baseline.
• Mean change in weight from baseline, using an intention-
to-treat (ITT) analysis, with last weight measure carried forward
for study dropouts and losses to follow up. Some of the findings
by ITT may be difficult to interpret as quitting is of itself
associated with weight gain.
We have considered weight change at the end of pharmacotherapy
and at the longest follow up.We have reported weight change for a
study of taranabant which was excluded from the studies reporting
outcomes for smoking cessation. The other excluded studies did
not report the effects of rimonabant on weight gain.
Other outcomes relevant to cardiovascular risk, for example lipid
levels, have been extracted if reported at long-term follow up.
Where appropriate, we have conducted a meta-analysis of the in-
cluded studies, using the Mantel-Haenszel risk ratio and a fixed-
effect model, provided that there was no significant heterogeneity.
Previous versions of this review reported the results as odds ratios,
but we have now revised our standard metric in an attempt to
clarify the findings.
We include in this review the Tobacco Addiction Group glossary
of tobacco-specific terms (Appendix 1).
R E S U L T S
Description of studies
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We identified three trials whichmet our inclusion criteria. All were
Phase III trials, funded andmanaged by themakers of rimonabant,
Sanofi Aventis. Two trials of identical design (STRATUS-EU
2006; STRATUS-US 2006) evaluated rimonabant for smoking
cessation, and one trial evaluated rimonabant as an aid to relapse
prevention (STRATUS-WW 2005).
The two cessation trials covered 1567 smokers, 1046 of whom
were on active treatment (20 mg or 5 mg). The relapse preven-
tion trial began with 5055 smokers, all of whom were on active
treatment. During the second phase the 1661 quitters were re-
randomized to a maintenance dose of active or placebo treatment
for a further 42 weeks. Full details of each trial are given in the
Table of Included Studies.
STRATUS-EU 2006 was a multi-centre study, set in seven Eu-
ropean countries (Sanofi 2003), while STRATUS-US 2006 was
conducted at a clinic in Pennsylvania. The relapse prevention trial
(STRATUS-WW2005)was set inCanada, Australia and theUSA.
All three trials tested rimonabant at dosage levels of 5 mg and
20 mg, and compared it with a placebo. For the cessation trials,
the treatment period was 10 weeks, with a target quit date set
for day 15, and follow up for an additional 40 weeks. In the
relapse prevention trial (STRATUS-WW 2005) participants who
achieved abstinence after 10 weeks of treatment on either a 5 mg
or a 20 mg regimen were then re-randomized to either 5 mg or
placebo (the 5 mg quitters) or to 5 mg, 20 mg or placebo (the 20
mgquitters) for a further 42weeks of relapse prevention treatment.
Successful abstainers at one year in this trial were then followed
for a further 52 weeks without treatment.
The cessation trials included brief behavioural counselling at
weekly visits throughout the treatment phase, covering cessation-
related topics such as craving and relapse prevention, and also
diet and exercise but without dietary restrictions. Brief counselling
continued at regular clinic visits throughout the follow-up phase.
The relapse prevention trial did not report on behavioural sup-
port.
The primary outcome for the cessation trials was continuous ab-
stinence through weeks 7 to 10 (end of treatment). Both trials also
reported the secondary outcome of continuous abstinence through
weeks 2 to 50, and also 7-day point prevalence abstinence at weeks
8, 10 and 50. Although cessation and/or relapse prevention were
the focus of the three trials, all of them also reported weight change
as a secondary outcome of interest. The relapse prevention trial
also reported on changes in HDL-cholesterol and in triglycerides.
Risk of bias in included studies
None of the rimonabant trials has reported their methods of ran-
domization or allocation concealment, and are therefore rated as
’unclear’ for their attempts to control selection bias.
In our dependence upon unpublished reports, we have sometimes
found the data to be inconsistent across different sources. The
denominators for the STRATUS-EU groups shift between sources
and within the same source.
All three trials defined their abstinence outcome as ’prolonged’
i.e. continuous after a post-quit date grace period of two weeks
(Hughes 2003), and biochemically verified at each visit by expired
carbon monoxide (CO) levels of 10 or fewer parts per million. In
the cessation trials, cotinine was also used to verify abstinence at
baseline, at weeks 8 and 10, and during the follow-up phase at
weeks 14, 32 and 50. The relapse prevention trial used exhaled
CO to verify abstinence during the 10-week cessation phase, and
has not reported its validation procedure for the relapse prevention
or the no-treatment phases.
Rates of non-completion of the treatment phase were around 30%
for STRATUS-US 2006, and around 40% for STRATUS-EU
2006, without significantly different losses between groups. Non-
completion rates for phases 1 and 2 have not been reported for the
relapse prevention trial, and none of the trials has reported long-
term losses to follow up.
Effects of interventions
Cessation
Both trials (STRATUS-EU 2006; STRATUS-US 2006) detected
a benefit of rimonabant 20 mg over placebo for prolonged ab-
stinence at 50 weeks, although the odds ratio (OR) for the
STRATUS-EU 2006 trial failed to reach statistical significance
(1.31, 95% confidence interval [CI] 0.83 to 2.09). The pooled
risk ratio (RR) for the two trials was 1.50 (95% CI 1.10 to 2.05;
comparison 01.01). The pooled RR for continuous abstinence at
end of treatment (7 to 10 weeks) was similar, at 1.46 (95%CI 1.16
to 1.85; comparison 01.02). No significant benefit of rimonabant
5 mg over placebo was demonstrated at either 50 weeks (RR 1.12,
95% CI 0.80 to 1.56; comparison 03.01) or at end of treatment
(RR 1.12, 95% CI 0.87 to 1.44; comparison 03.02).
We compared the effect of the two doses of rimonabant for pro-
longed abstinence at 50 weeks and at end of treatment across both
trials, and found a modest benefit of the 20 mg regimen over the 5
mg regimen: RR 1.35, 95% CI 1.00 to 1.82 at 50 weeks (compari-
son 04.01), and RR 1.31, 95%CI 1.05 to 1.64 at end of treatment
(comparison 04.02).
Relapse prevention
At the end of the phase 1 10-week treatment regimen in
STRATUS-WW 2005, both the 5 mg and the 20 mg groups had
similar cessation rates of 31.8% and 33.6% respectively. Those 5
mg quitters who were then randomized to the same treatment for
phase 2 did not differ significantly from the 5 mg/placebo quitters
in relapse rates at 52 weeks. The phase 1 20 mg quitters who were
then randomized to the two active treatment groups in phase 2
maintained significantly higher cessation rates than the placebo
group, with an RR for the phase 2 20 mg group of 1.29 (95%
CI 1.06 to 1.57; comparison 02.01) and an RR for the phase 2
5 mg group of 1.30 (95% CI 1.06 to 1.59; comparison 02.02),
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compared with placebo. Phase 2 participants were scheduled to
be followed up for a period of 104 weeks, but we have no results
beyond the 52-week outcomes described here.
Weight change
Findings for those maintaining abstinence from smoking:
Among participants maintaining smoking abstinence from 2 to
48 weeks after their quit date, a pooled analysis for STRATUS-EU
2006 and STRATUS-US 2006 shows that those on rimonabant
20 mg gained significantly less weight than those on 5 mg or
placebo (P < 0.05; STRATUS-EU 2006). There was no significant
difference for 5 mg versus placebo. Separate data for the American
and European trials were not presented. At the 52-week follow
up in STRATUS-WW 2005, among those avoiding relapse to
smoking post-cessation weight gain was significantly lower in the
rimonabant 20 mg group versus placebo (P < 0.001). Weight gain
was similar in the placebo and rimonabant 5 mg groups. The
extent of the weight gain in STRATUS-WW 2005 was shown
graphically, but not reported as absolute changes in kilos.
In a pooled analysis of STRATUS-US 2006 and STRATUS-EU
2006, among those remaining abstinent from smoking throughout
the final four weeks of treatment, those taking rimonabant 20 mg
gained significantly less weight than those on placebo (P < 0.001),
although it is unclear whether this was measured at ten or at 48
weeks. There were no significant differences when comparing 5
mg rimonabant with placebo. In STRATUS-EU 2006, among
non-obese participants, the rimonabant 20 mg users (N = 54) had
a mean weight gain of 0.5 kg; for rimonabant 5 mg (users N =
53) the gain was 1.6 kg; those on placebo (N = 44) gained 2.3
kg. Details of weight changes were not given for STRATUS-US
2006.
Findings using intention-to-treat (ITT) analysis:
When considering all those smokers who were randomized (ITT
analysis), in the STRATUS-US 2006 trial, on average across the
10-week treatment period, those on rimonabant 20 mg lost 0.3
kg, while those on placebo gained 1.1 kg (P < 0.001). Participants
who were overweight (body mass index [BMI: weight in kg/height
in m2] = 25 to 29.9) or obese (BMI = 30+) tended to lose weight
using rimonabant 20 mg, while normal-weight participants (BMI
=18.5 to 24.9) did not.Overweight smokers on rimonabant 20mg
lost 0.5 kg on average, versus a gain of 0.9 kg for those on placebo.
Obese smokers on rimonabant 20 mg lost 0.6 kg compared with
a gain of 1.3 kg for those on placebo. For those of normal weight
there was no weight change when using rimonabant 20 mg, but
those on placebo gained 1.0 kg.Only the finding for obese smokers
reached statistical significance (P < 0.001). Weight change for the
rimonabant 5 mg group was not reported.
Again using an ITT analysis, in STRATUS-EU 2006 those on
rimonabant 20 mg (N = 267) lost 0.5 kg, while those on placebo
(N = 260) and 5 mg (N = 256) gained 1.0 kg and 0.2 kg re-
spectively, across the treatment period. In STRATUS-WW 2005,
among all re-randomized participants at the 52 week follow-up,
those on rimonabant 20 mg (N=340), 5 mg (N=335) and placebo
(N=342) gained an average of 0.6 kg, 1.9 kg and 2.0 kg respec-
tively. As with STRATUS-US 2006, for STRATUS-EU 2006 and
STRATUS-WW 2005 the difference in weight gain for 20 mg
versus placebo reached statistical significance (P = 0.001, P < 0.001
respectively). Where there were missing data, the ITT analysis for
STRATUS-EU 2006 and STRATUS-WW 2005 was based on
’last observation carried forward’. It is not clear whether this ap-
proach was also used for the ITT analysis for STRATUS-US 2006.
A study of taranabant (Morrison 2010), excluded from the re-
port of findings for smoking cessation outcomes, reported weight
change using ITT analysis for a comparison of taranabant (2-8
mg) versus placebo. After eight weeks of treatment, participants
on taranabant lost an average of 1.5 kg, while those on placebo
gained 0.6 kg. This difference reached statistical significance (P <
0.001).
Adverse events:
The three rimonabant trials demonstrated disparate patterns of
adverse events. STRATUS-US 2006 reported nausea as the most
frequent side effect, occurring in 15.7% of the 20 mg group com-
pared with 9.2% in the 5 mg group and 8.8% in the control group
(differences not statistically significant). This paralleled the pre-
dominance and rates of nausea as the main side effect reported in
the RIO trials, which tested rimonabant as a treatment for weight
control (Curioni 2006). Nausea was not mentioned as a signifi-
cant side effect in STRATUS-EU 2006, which listed fatigue, de-
pressed mood, anxiety and nasopharyngitis as themost commonly
reported events. Upper respiratory tract infection was the most
frequent adverse event for the STRATUS-WW2005 participants,
at around 18% across all groups, with nasopharyngitis as the next
most commonly reported event (mean 10.5% across all groups).
Again, nausea was not mentioned as a significant side effect for
any group in this trial. It should be noted, however, that the Sum-
mary of Product Characteristics (Acomplia SPC 2006) reports the
incidence of nausea and upper respiratory tract infections as ’very
common’ (i.e. > 10%) when rimonabant is used for weight con-
trol.
Drop-out rates attributable to adverse events were consistently
highest in the 20 mg groups and lowest in the control groups, with
only STRATUS-EU 2006 reporting a statistically significantly
higher drop-out rate in the 20 mg group (14.6%) compared with
the placebo group (6.9%; P = 0.004). STRATUS-EU 2006 re-
ported significantly higher rates of drop-out attributable to adverse
events across all groups (placebo 6.9%, 5mg 9.8%, 20 mg 14.6%)
compared with STRATUS-US 2006 (3.8%, 5.7%, 6.9% respec-
tively) and with STRATUS-WW 2005 (6.1%, 6.3%, 9.7% re-
spectively). However, the STRATUS-EU 2006 attributable drop-
out rates were similar to those reported in the four RIO trials
(Curioni 2006).
Information on serious adverse events (SAEs) is sparse. At one year
follow up, STRATUS-WW 2005 reports SAE rates of 5%, 3.6%
and5.3% inplacebo, 5mg and20mggroups respectively. The cor-
responding figures for STRATUS-EU 2006 are 2.7%, 0.8% and
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2.2%, i.e. the placebo group reporting the highest rate, but with
a statistically non-significant difference. STRATUS-US 2006 has
not reported separate group rates, but has confirmed that no car-
diovascular safety concerns were raised by their findings. A pooled
analysis of STRATUS-EU, STRATUS-META and STRATUS-
US reports SAEs running at 2% in the rimonabant 20 mg group
compared with 2.2% in the placebo group (STRATUS META
2006). This may be compared with SAE rates in the RIO (rimona-
bant in obesity) trials, which ranged from4% to 8%,with a pooled
relative risk increase of 1.37 (95% CI 1.04 to 1.80, P = 0.03) in
the 20 mg groups compared with placebo groups (Curioni 2006).
Since the initial publication of our review in The Cochrane Library
2007 Issue 3, there have been trial reports of episodes of depres-
sion (in up to 10% of participants) and suicidal thoughts (in up to
1%), with possibly an increased risk in patients with a past history
of psychiatric illness. In the USA, the FDA advisory board (FDA
2007) voted unanimously not to approve the drug for any use at
present, until further data on its risk-benefit profile are available.
In October 2008, the European Medicines Agency (EMEA) in-
structed Sanofi Aventis to withdraw rimonabant, because of links
with mental disorders (Sanofi Aventis 2008). There now seems no
prospect of it ever being approved in any part of the world as an
aid for smoking cessation.
Morrison 2010 demonstrated no clear benefit of taranabant over
placebo for smoking cessation, returning an OR for continuous
abstinence at eight weeks of 1.2 (90% CI 0.6 to 2.5). Because the
trial did not report abstinence rates beyond week eight (end of
treatment), we have not included it in our meta-analyses. How-
ever, it provides data for consideration of adverse events. Dur-
ing the treatment phase, 83.6% of participants in the taranabant
group suffered clinical adverse events, comparedwith 69.6%of the
placebo group. SAE rates were 2.5% for the taranabant group ver-
sus 0.6% for the placebo group.Discontinuations ran at 12.6% for
taranabant users versus 3.2% of those on placebo. The four SAEs
in the taranabant group were agitation, palpitations, melanoma,
and basal cell carcinoma, none of which was attributed directly to
the active treatment. There was no suicidal behaviour by any par-
ticipant during the treatment period, although suicidal ideation
was reported in 3.2% of the taranabant group, compared with
none in the placebo group. There were no significant differences
in adverse events or SAEs between the groups during the post-
treatment six-week follow-up period.
Taranabant as a treatment for obesity was found in another trial
to be effective at relatively low doses (2 mg and 4 mg) over a
two-year test period (Aronne 2010). However, the incidence of
adverse events (gastrointestinal, nervous, psychiatric, cutaneous
and vascular organ systems) was found to be dose-related, and was
deemed unacceptable. The manufacturers (Merck & Co) decided
in 2008 to discontinue further development of the drug for any
indication.
D I S C U S S I O N
Our review has suffered from a lack of peer-reviewed and pub-
lished study reports. Despite our best efforts to obtain informa-
tion, we have had to rely on conference presentations, press releases
and pharmaceutical company reports, and we are aware that the
findings of this review are tentative and incomplete. We currently
lack much methodological detail, including randomization and
allocation procedures, exclusion criteria, verificationmethods, and
levels of behavioural support. We would also welcome full details
of attrition rates, losses to follow up, individual trial results and
comprehensive long-term outcome data. Furthermore, all the tri-
als reviewed were sponsored by the pharmaceutical company man-
ufacturing rimonabant. Since conflicts of interest could influence
the results, their findings should be treated with caution.
Smoking cessation
Two cessation trials have detected a benefit of rimonabant 20 mg
over placebo at longest reported follow up, with a statistically sig-
nificant pooled risk ratio (RR) of 1.50. There was also a mod-
est but significant benefit of the 20 mg dose over the 5 mg dose
(pooled RR 1.35). These data are compatible with rimonabant’s
failure at the 5 mg dose to out-perform placebo treatment in these
trials.
The pooled results mask the differential between the findings of
the two trials. STRATUS-EU 2006 consistently failed to demon-
strate the superiority of rimonabant 20 mg over either placebo or
rimonabant 5 mg for prolonged abstinence at either 50 weeks or
at end of treatment (7 to 10 weeks). STRATUS-US 2006 found
statistically significant benefits for the 20 mg regimen for both
comparisons and at both time points. The failure of rimonabant
20mg to establish a significant benefit in the STRATUS-EU 2006
trial can be largely attributed to an exceptionally high placebo quit
rate (19.6% at end of treatment, 14.6% at 50 weeks). This sus-
tained discrepancy between the two trials weakens the validity of
the findings.
Relapse prevention
It is worth noting that for the phase 1 (cessation) 20 mg quitters in
STRATUS-WW 2005, those randomized to a 5 mg maintenance
dose (RR of 1.30 compared with placebo at 52 weeks) did at least
as well as those randomized to a 20 mg maintenance dose (RR
1.29). This finding is difficult to interpret; considering only the
phase 1 group who quit on 20 mg, it would suggest that the lower
dose of maintenance therapy is as effective as the higher dose,
and that both regimens yield better success rates than placebo
treatment. However, for the phase 1 group who quit on 5 mg,
randomized either to 5 mg or to placebo during the maintenance
phase, the active treatment group did no better than the placebo
group, suggesting that the presence or absence of treatment made
no difference during the maintenance phase. Since the quit rates
in both phase 1 groups were similar (31.8% in the 5 mg group
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versus 33.6% in the 20 mg group), we have no consistent evidence
from this trial for the relative efficacy of the two doses, either
for cessation or for maintenance. We also lack information on
the phase 3 findings, which covered a further 52 weeks without
treatment.
Weight change
Among abstinent smokers, we found a statistically significant effect
of rimonabant 20 mg on body weight. Compared with placebo,
rimonabant 20 mg produced significantly less weight gain at end
of treatment in two trials. Only one of these trials reported the
magnitude of the weight reduction and only for non-obese par-
ticipants. In this study those on rimonabant gained 1.8 kg less
than those on placebo. At 48-week follow-up a pooled analysis of
the two trials showed that there was significantly less weight gain
for rimonabant 20 mg versus placebo, among those maintaining
abstinence. However, a separate analysis for each trial was not pre-
sented. In the trial of relapse prevention, those avoiding relapse
up to 52 weeks gained significantly less weight on rimonabant
20 mg versus placebo, but the magnitude of the weight gain was
not given. Using an intention to treat (ITT) approach, one trial
showed significantly less weight gain for rimonabant 20 mg versus
placebo at end of treatment, and another study showed the same
benefit at 52 weeks follow-up. However, both these analyses were
based on ’last observation carried forward’, which makes interpre-
tation difficult (see comments below). In addition, only one of
these trials presented the weight changes and in this study those on
rimonabant 20 mg gained just 1.4 kg less than those on placebo at
52 weeks. The third trial reported a significant benefit of rimona-
bant 20mg, compared with placebo, on weight gain only for obese
individuals. Overall, the findings suggest that rimonabant 20 mg
may have a modest benefit for moderating weight gain following
smoking cessation both in the short-term and the long-term, but
the magnitude of this benefit is not clear and methodological lim-
itations make interpretation problematic. Without further data it
is not possible to judge the clinical significance of any benefits for
rimonabant on weight gain.
In nearly all cases the magnitude of the weight change was not re-
ported or was reported only for a sub-sample, and in no cases were
95% confidence intervals given. For two trials the key outcome
of weight change among confirmed quitters at the final follow up
was reported using only a pooled analysis combining data from
both studies. None of the studies presented an analysis exclusively
for those who relapsed or continued to smoke. Only one report
examined weight changes according to whether participants were
obese, overweight or of normal weight at baseline. The outcomes
for prolonged smoking cessation were based on the recommended
two-week grace period (Hughes 2003), whereas weight change was
assessed among those who had abstained following a four-week
grace period. It is not clear why this unconventional criterion for
prolonged abstinence was used for weight change.
For the ITT analysis, where there were missing weight data the
last observation was carried forward. This approach makes the
unrealistic assumption that weight remains constant since the last
measurement. Consequently, the results may have been biased in
either direction. For example, if those on placebo dropped out of
the study because they were gaining weight, then carrying the last
observation forward is likely to underestimate their weight gain.
This may then lead to underestimation of the benefit of rimona-
bant compared with placebo. Conversely, if some of those on ri-
monabant withdrew because of weight gain, then carrying their
last observation forward may underestimate the mean weight gain
in this group. The benefit of rimonabant versus placebo would in
that case be overestimated. As the attrition rates were not reported
it is not possible to estimate the extent of this problem. High at-
trition rates would compromise the validity of an ITT analysis.
The obvious solution would be to measure all participants, even
if they did not adhere to the treatment. Another issue related to
drop-outs is that it is possible that some individuals did not take
rimonabant as prescribed but still managed to stop smoking with
little weight gain and attended the follow-up visits. The number
of these individuals is not given, and this may distort the results
in a way that overestimates the benefit of rimonabant for weight
loss.
The taranabant trial, excluded from the analysis for smoking ces-
sation outcomes, reported a benefit for taranabant over placebo
in reducing or eliminating weight gain by end of treatment (eight
weeks). An ITT analysis was used, with the last observation carried
forward in the case of missing data. As discussed in the previous
paragraph, this approach may compromise the results.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
• From the limited evidence available, rimonabant 20 mg
increased by about 1½-fold the chances of long-term cessation.
The 5 mg dose appeared to confer no significant benefit.
However, in the absence of detailed peer-reviewed reports, the
trial findings remain inconsistent and provisional.
• Taranabant as an aid to smoking cessation (assessed after
eight weeks of treatment) was not found to confer significant
benefit over placebo treatment.
• Adverse events for rimonabant may be dose-related, and
may include upper respiratory tract infection and nausea. The
severity and type of adverse event were inconsistent across the
three trials included in this review.
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• Rates of serious adverse events were reported in the trials to
be low. However, the use of rimonabant as an aid to weight loss
was suspended in European countries in October 2008, because
of links to mental disorders including depression and suicidal
thoughts. Adverse events for taranabant were dose-related, and
contributed to the manufacturer’s decision in 2008 to suspend
development of the drug for any indication.
• Partial study reports, without long-term outcomes at the
end of the no-treatment phase, preclude any clear findings on the
use of rimonabant for maintenance of abstinence.
• Based on the findings of one study, rimonabant 20 mg may
moderate weight gain among those who abstain from smoking
for approximately one year. There is insufficient information
from the other two trials to substantiate this finding.
• Based on the findings of one study, taranabant 2-8 mg may
moderate weight gain by the end of eight weeks of treatment.
Implications for research
• Rimonabant’s withdrawal as a prescription drug in Europe
and the FDA’s decision not to license it for any indication make
it unlikely that rimonabant will ever be approved anywhere as an
aid to smoking cessation.
• Taranabant’s lack of efficacy for smoking cessation,
combined with an unacceptable adverse events profile, means
that it will no longer be developed or promoted either for obesity
or for smoking cessation.
• Although neither drug will be licensed or promoted for
smoking cessation, the principle of modulating the
endocannabinoid system to reduce urges to smoke remains a
plausible approach, provided that adverse events can be reduced
to acceptable levels.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
STRATUS-EU 2006
Methods SMOKING CESSATION
Country: Belgium, Denmark, France, Spain, Sweden, Switzerland, UK
Setting:
Study Design: Double-blind placebo-controlled parallel-assignment RCT.
Analysis: Logistic regression on ITT basis.
Participants 783 adults (>=18) smoking at least 10 CPD. Randomized to rimonabant 5mg (N=256)
, rimonabant 20mg (N=267), or placebo (N=260).
46% M, 98% W, mean age 42.4, av CPD 22.5, mean yrs smoking 24.9, mean quit
attempts 2.9, mean FTND score 5.6, 35% with a FTND score >7. Mean BMI 25.0
Interventions (i) Rimonabant 5 mg (ii) Rimonabant 20 mg (iii) Placebo tablets
2-wk pre-treatment screening period, then 10 wks treatment, with TQD at day 15.
Behavioural support:
Treatment phase: Participants were seen weekly for 12 wks (-2 to +10 wks). Brief be-
havioural counselling at every visit on tobacco-related topics (e.g. craving, relapse pre-
vention) including diet and exercise, but no dietary restrictions.
Follow-up phase: clinic visits at wks 11, 14, 22, 30, 39, 48
Outcomes Primary outcome: Continuous validated abstinence at 7-10 wks. Maximum follow up:
48 wks. Strictest measure of abstinence: Prolonged validated abstinence from tobacco or
nicotine products from wk 2 to wk 48.
Validation method: Expired CO <10ppm at all visits, + cotinine at baseline, wks 8 and
10, and at wks 14, 32 and 50.
Other outcomes: weight change; adverse events.
Notes Identical design to STRATUS-US trial.
Trial was funded by the manufacturers, Sanofi Aventis.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Reported as double-blind, but no details
given
Other bias Unclear risk Not stated
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STRATUS-US 2006
Methods SMOKING CESSATION
Country: USA
Setting: Sanofi Clinic, Pennsylvania
Study Design: Double-blind placebo-controlled parallel-assignment RCT.
Analysis: Logistic regression on ITT basis.
Participants 784 adults (>=18) smoking at least 10 CPD. Randomized to rimonabant 5mg (N=262)
, rimonabant 20mg (N=261), or placebo (N=261).
51% M, 87% W, mean age 42.3, av CPD 23.6, mean yrs smoking 24.1, mean quit
attempts 4.1, mean FTND score 5.4, 31.7% with a FTND score >7. Mean BMI 27.8
Interventions (i) Rimonabant 5 mg (ii) Rimonabant 20 mg (iii) Placebo tablets
2-wk pre-treatment screening period, then 10 wks treatment, with TQD at day 15.
Behavioural support:
Treatment phase: Participants were seen weekly for 12 wks (-2 to +10 wks). Brief be-
havioural counselling at every visit on tobacco-related topics (e.g. craving, relapse pre-
vention) including diet and exercise, but no dietary restrictions.
Follow-up phase: clinic visits at wks 11, 14, 22, 30, 39, 48
Outcomes Primary outcome: Continuous validated abstinence at 7-10 wks. Maximum follow up:
48 wks. Strictest measure of abstinence: Prolonged validated abstinence from tobacco or
nicotine products from wk 2 to wk 48.
Validation method: Expired CO <10ppm at all visits, + cotinine at baseline, wks 8 and
10, and at wks 14, 32 and 50.
Other outcomes: weight change; adverse events.
Notes Identical design to STRATUS-EU trial.
Trial was funded by the manufacturers, Sanofi Aventis.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Reported as double-blind, but no details
supplied
Other bias Unclear risk Not stated
14Cannabinoid type 1 receptor antagonists for smoking cessation (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
STRATUS-WW 2005
Methods RELAPSE PREVENTION TRIAL
Country: Australia, Canada, USA
Study Design: Double-blind placebo-controlled parallel-assignment RCT.
Analysis: Logistic regression on ITT basis.
Participants 5055 adult smokers (>+18) motivated to quit. randomized to rimonabant 5mg (N=
2026) or rimonabant 20mg (N=3029).
50% M, 88.8% W, mean age 44.1, av CPD 23.6, mean yrs smoking 24.1, mean quit
attempts 4.1, mean FTND score 5.4, 31.7% with a FTND score >7. Mean BMI 27.8
Interventions Phase 1: Cessation: Participants randomized to rimonabant 5mg [R5] (N=2026) or
rimonabant 20mg [R20] (N=3029) for 10 wks, with TQD at day 15. Cessation rates
at EoT: R5: 644/2026 (31.8%); R20 1017/3029 (33.6%), difference non-significant;
Quitters eligible for Phase 2 if: (a) self-reported abstinence for 7+ days, (b) CO <=
10ppm, and (c) compliance level of 80%+ in last 4 wks of Phase 1.
Phase 2: Relapse prevention: Re-randomized 644 quitters in R5 group to (i) R5 (N=
322) or (ii) placebo (N=322), and 1017 quitters in R20 group to (i) R5 (N=335) or (ii)
R20 (N=340) or (iii) placebo (N=342). All groups received treatment for a further 42
wks.
Behavioural support: Not reported.
Outcomes Primary outcome: Time to relapse for quitters from wks 10 to 32. Relapse defined as >=
7 consecutive days of smoking (even a puff ), or >= 2 consecutive days with >= 5 cigs
(even a puff ) smoked per day.
Long-term follow up: 52 wks, 104 wks.
Secondary outcome: time to relapse for quitters from wks 10 to 52.
Other outcomes: weight change; fasting HDL-cholesterol, triglycerides; safety, adverse
events.
Validation: Phase 1: expired CO <10ppm; Phase 2: not reported
Notes Two-year follow-up data were not reported.
Trial was funded by the manufacturers, Sanofi Aventis.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Reported as double-blind, but no details
given.
Other bias Unclear risk Not stated
BMI: body mass index (metric measure of weight/height squared)
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CPD: cigarettes per day
EoT: end of treatment
FTND: Fagerstrom Test for Nicotine Dependence
ITT: Intention to treat (includes all randomized in original groups)
M: male
TQD: target quit date
W: white
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Morrison 2010 RCT of 317 smokers randomized to taranabant 2-8 mg daily vs placebo. Trial lasted 8 wks, with primary
outcome PPA for wks 5-8. Adverse events covered in Discussion section
Rigotti 2009 The CIRRUS trial. RCT of 755 smokers; all received open-label rimonabant. Intervention being tested
was the addition of an active nicotine patch or placebo patch
STRATUS META 2006 RCT in USA of 530 smokers randomized to rimonabant 20mg or placebo; cessation reported at 10 wks,
EoT, with no long-term follow up
Topol 2010 CRESCENDO trial: Multicentre in 42 countries, with 18,695 pts. Trial was prematurely discontinued
in November 2008, because of concerns at raised levels of gastrointestinal, neuropsychiatric and serious
psychiatric side effects in rimonabant pts compared with placebo pts. Four rimonabant pts had committed
suicide, compared with 1 placebo pt
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Comparison 1. Rimonabant 20mg vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Prolonged abstinence at wk 50 2 1049 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [1.10, 2.05]
2 Continuous 4-wk abstinence at
EOT (wks 7-10)
2 1049 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [1.16, 1.85]
Comparison 2. Relapse prevention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 rimonabant 20mg vs placebo at
52 weeks
1 682 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [1.06, 1.57]
2 rimonabant 5mg vs placebo at
52 weeks
1 677 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [1.06, 1.59]
Comparison 3. Rimonabant 5mg vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Prolonged abstinence at wk 50 2 1039 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.80, 1.56]
2 Continuous 4-wk abstinence at
EOT (wks 7-10)
2 1039 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.87, 1.44]
Comparison 4. Rimonabant 20mg vs rimonabant 5mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Prolonged abstinence at wk 50 2 1046 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [1.00, 1.82]
2 Continuous 4-wk abstinence at
EOT (wks 7-10)
2 1046 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [1.05, 1.64]
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Analysis 1.1. Comparison 1 Rimonabant 20mg vs placebo, Outcome 1 Prolonged abstinence at wk 50.
Review: Cannabinoid type 1 receptor antagonists for smoking cessation
Comparison: 1 Rimonabant 20mg vs placebo
Outcome: 1 Prolonged abstinence at wk 50
Study or subgroup rimonabant placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
STRATUS-EU 2006 49/267 38/260 67.0 % 1.26 [ 0.85, 1.85 ]
STRATUS-US 2006 38/261 19/261 33.0 % 2.00 [ 1.19, 3.38 ]
Total (95% CI) 528 521 100.0 % 1.50 [ 1.10, 2.05 ]
Total events: 87 (rimonabant), 57 (placebo)
Heterogeneity: Chi2 = 1.97, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 2.57 (P = 0.010)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours rimonabant
Analysis 1.2. Comparison 1 Rimonabant 20mg vs placebo, Outcome 2 Continuous 4-wk abstinence at EOT
(wks 7-10).
Review: Cannabinoid type 1 receptor antagonists for smoking cessation
Comparison: 1 Rimonabant 20mg vs placebo
Outcome: 2 Continuous 4-wk abstinence at EOT (wks 7-10)
Study or subgroup rimonabant placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
STRATUS-EU 2006 66/267 51/260 55.2 % 1.26 [ 0.91, 1.74 ]
STRATUS-US 2006 72/261 42/261 44.8 % 1.71 [ 1.22, 2.41 ]
Total (95% CI) 528 521 100.0 % 1.46 [ 1.16, 1.85 ]
Total events: 138 (rimonabant), 93 (placebo)
Heterogeneity: Chi2 = 1.66, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 3.20 (P = 0.0014)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours rimonabant
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Analysis 2.1. Comparison 2 Relapse prevention, Outcome 1 rimonabant 20mg vs placebo at 52 weeks.
Review: Cannabinoid type 1 receptor antagonists for smoking cessation
Comparison: 2 Relapse prevention
Outcome: 1 rimonabant 20mg vs placebo at 52 weeks
Study or subgroup rimonabant placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
STRATUS-WW 2005 141/340 110/342 100.0 % 1.29 [ 1.06, 1.57 ]
Total (95% CI) 340 342 100.0 % 1.29 [ 1.06, 1.57 ]
Total events: 141 (rimonabant), 110 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.012)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours rimonabant
19Cannabinoid type 1 receptor antagonists for smoking cessation (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Relapse prevention, Outcome 2 rimonabant 5mg vs placebo at 52 weeks.
Review: Cannabinoid type 1 receptor antagonists for smoking cessation
Comparison: 2 Relapse prevention
Outcome: 2 rimonabant 5mg vs placebo at 52 weeks
Study or subgroup rimonabant placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
STRATUS-WW 2005 140/335 110/342 100.0 % 1.30 [ 1.06, 1.59 ]
Total (95% CI) 335 342 100.0 % 1.30 [ 1.06, 1.59 ]
Total events: 140 (rimonabant), 110 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.58 (P = 0.010)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours rimonabant
Analysis 3.1. Comparison 3 Rimonabant 5mg vs placebo, Outcome 1 Prolonged abstinence at wk 50.
Review: Cannabinoid type 1 receptor antagonists for smoking cessation
Comparison: 3 Rimonabant 5mg vs placebo
Outcome: 1 Prolonged abstinence at wk 50
Study or subgroup rimonabant placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
STRATUS-EU 2006 43/256 38/260 66.5 % 1.15 [ 0.77, 1.72 ]
STRATUS-US 2006 20/262 19/261 33.5 % 1.05 [ 0.57, 1.92 ]
Total (95% CI) 518 521 100.0 % 1.12 [ 0.80, 1.56 ]
Total events: 63 (rimonabant), 57 (placebo)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours rimonabant
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Analysis 3.2. Comparison 3 Rimonabant 5mg vs placebo, Outcome 2 Continuous 4-wk abstinence at EOT
(wks 7-10).
Review: Cannabinoid type 1 receptor antagonists for smoking cessation
Comparison: 3 Rimonabant 5mg vs placebo
Outcome: 2 Continuous 4-wk abstinence at EOT (wks 7-10)
Study or subgroup rimonabant placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
STRATUS-EU 2006 62/256 51/260 54.6 % 1.23 [ 0.89, 1.71 ]
STRATUS-US 2006 41/262 42/261 45.4 % 0.97 [ 0.66, 1.44 ]
Total (95% CI) 518 521 100.0 % 1.12 [ 0.87, 1.44 ]
Total events: 103 (rimonabant), 93 (placebo)
Heterogeneity: Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours rimonabant
Analysis 4.1. Comparison 4 Rimonabant 20mg vs rimonabant 5mg, Outcome 1 Prolonged abstinence at wk
50.
Review: Cannabinoid type 1 receptor antagonists for smoking cessation
Comparison: 4 Rimonabant 20mg vs rimonabant 5mg
Outcome: 1 Prolonged abstinence at wk 50
Study or subgroup rimonabant 20 rimonabant 5 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
STRATUS-EU 2006 49/267 43/256 68.7 % 1.09 [ 0.75, 1.58 ]
STRATUS-US 2006 38/261 20/262 31.3 % 1.91 [ 1.14, 3.19 ]
Total (95% CI) 528 518 100.0 % 1.35 [ 1.00, 1.82 ]
Total events: 87 (rimonabant 20), 63 (rimonabant 5)
Heterogeneity: Chi2 = 2.98, df = 1 (P = 0.08); I2 =66%
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours R5 Favours R 20
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Analysis 4.2. Comparison 4 Rimonabant 20mg vs rimonabant 5mg, Outcome 2 Continuous 4-wk abstinence
at EOT (wks 7-10).
Review: Cannabinoid type 1 receptor antagonists for smoking cessation
Comparison: 4 Rimonabant 20mg vs rimonabant 5mg
Outcome: 2 Continuous 4-wk abstinence at EOT (wks 7-10)
Study or subgroup rimonabant 20 rimonabant 5 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
STRATUS-EU 2006 66/267 62/256 60.7 % 1.02 [ 0.76, 1.38 ]
STRATUS-US 2006 72/261 41/262 39.3 % 1.76 [ 1.25, 2.48 ]
Total (95% CI) 528 518 100.0 % 1.31 [ 1.05, 1.64 ]
Total events: 138 (rimonabant 20), 103 (rimonabant 5)
Heterogeneity: Chi2 = 5.52, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours R5 Favours R20
A P P E N D I C E S
Appendix 1. Glossary of tobacco-specific terms
Term Definition
Abstinence A period of being quit, i.e. stopping the use of cigarettes or other tobacco products,
May be defined in various ways; see also:
point prevalence abstinence; prolonged abstinence; continuous/sustained abstinence
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(Continued)
Biochemical verification Also called ’biochemical validation’ or ’biochemical confirmation’:
A procedure for checking a tobacco user’s report that he or she has not smoked or used
tobacco. It can be measured by testing levels of nicotine or cotinine or other chemicals
in blood, urine, or saliva, or by measuring levels of carbon monoxide in exhaled breath
or in blood
Bupropion A pharmaceutical drug originally developed as an antidepressant, but now also licensed
for smoking cessation; trade names Zyban, Wellbutrin (when prescribed as an antide-
pressant)
Carbon monoxide (CO) A colourless, odourless highly poisonous gas found in tobacco smoke and in the lungs
of people who have recently smoked, or (in smaller amounts) in people who have been
exposed to tobacco smoke. May be used for biochemical verification of abstinence
Cessation Also called ’quitting’
The goal of treatment to help people achieve abstinence from smoking or other tobacco
use, also used to describe the process of changing the behaviour
Continuous abstinence Also called ’sustained abstinence’
A measure of cessation often used in clinical trials involving avoidance of all tobacco
use since the quit day until the time the assessment is made. The definition occasionally
allows for lapses. This is the most rigorous measure of abstinence
’Cold Turkey’ Quitting abruptly, and/or quitting without behavioural or pharmaceutical support
Craving A very intense urge or desire [to smoke].
See: Shiffman et al ’Recommendations for the assessment of tobacco craving and with-
drawal in smoking cessation trials’
Nicotine & Tobacco Research 2004: 6(4): 599-614
Dopamine A neurotransmitter in the brain which regulates mood, attention, pleasure, reward,
motivation and movement
Efficacy Also called ’treatment effect’ or ’effect size’:
The difference in outcome between the experimental and control groups
Harm reduction Strategies to reduce harm caused by continued tobacco/nicotine use, such as reducing
the number of cigarettes smoked, or switching to different brands or products, e.g.
potentially reduced exposure products (PREPs), smokeless tobacco
Lapse/slip Terms sometimes used for a return to tobacco use after a period of abstinence. A
lapse or slip might be defined as a puff or two on a cigarette. This may proceed to
relapse, or abstinence may be regained. Some definitions of continuous, sustained or
prolonged abstinence require complete abstinence, but some allow for a limited number
or duration of slips. People who lapse are very likely to relapse, but some treatments
may have their effect by helping people recover from a lapse
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(Continued)
nAChR [neural nicotinic acetylcholine receptors]: Areas in the brain which are thought to
respond to nicotine, forming the basis of nicotine addiction by stimulating the overflow
of dopamine
Nicotine An alkaloid derived from tobacco, responsible for the psychoactive and addictive effects
of smoking
Nicotine Replacement Therapy (NRT) A smoking cessation treatment in which nicotine from tobacco is replaced for a limited
period by pharmaceutical nicotine. This reduces the craving and withdrawal experi-
enced during the initial period of abstinence while users are learning to be tobacco-free
The nicotine dose can be taken through the skin, using patches, by inhaling a spray, or
by mouth using gum or lozenges
Outcome Often used to describe the result being measured in trials that is of relevance to the
review. For example smoking cessation is the outcome used in reviews of ways to help
smokers quit. The exact outcome in terms of the definition of abstinence and the length
of time that has elapsed since the quit attempt was made may vary from trial to trial
Pharmacotherapy A treatment using pharmaceutical drugs, e.g. NRT, bupropion
Point prevalence abstinence (PPA) A measure of cessation based on behaviour at a particular point in time, or during a
relatively brief specified period, e.g. 24 hours, 7 days. It may include a mixture of recent
and long-term quitters. cf. prolonged abstinence, continuous abstinence
Prolonged abstinence A measure of cessation which typically allows a ’grace period’ following the quit date
(usually of about two weeks), to allow for slips/lapses during the first few days when
the effect of treatment may still be emerging.
See:Hughes et al ’Measures of abstinence in clinical trials: issues and recommendations’;
Nicotine & Tobacco Research, 2003: 5 (1); 13-25
Relapse A return to regular smoking after a period of abstinence
Secondhand smoke Also called passive smoking or environmental tobacco smoke [ETS]
A mixture of smoke exhaled by smokers and smoke released from smouldering
cigarettes, cigars, pipes, bidis, etc. The smoke mixture contains gases and particulates,
including nicotine, carcinogens and toxins
Self-efficacy The belief that one will be able to change one’s behaviour, e.g. to quit smoking
SPC [Summary of Product Characteristics] Advice from the manufacturers of a drug, agreed with the relevant licensing authority,
to enable health professionals to prescribe and use the treatment safely and effectively
Tapering A gradual decrease in dose at the end of treatment, as an alternative to abruptly stopping
treatment
Titration A technique of dosing at low levels at the beginning of treatment, and gradually in-
creasing to full dose over a few days, to allow the body to get used to the drug. It is
designed to limit side effects
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(Continued)
Withdrawal A variety of behavioural, affective, cognitive and physiological symptoms, usually tran-
sient, which occur after use of an addictive drug is reduced or stopped.
See: Shiffman et al ’Recommendations for the assessment of tobacco craving and with-
drawal in smoking cessation trials’
Nicotine & Tobacco Research 2004: 6(4): 599-614
WH A T ’ S N E W
Last assessed as up-to-date: 25 January 2011.
Date Event Description
7 June 2012 Amended Minor correction made (no effect on content)
H I S T O R Y
Protocol first published: Issue 3, 2005
Review first published: Issue 3, 2007
Date Event Description
25 January 2011 New citation required and conclusions have changed Taranabant trial information on efficacy and adverse
events, leading to suspension of the drug
25 January 2011 New search has been performed Three trials added to excluded studies; risk of bias tables
completed
7 November 2008 Amended From October 2008, rimonabant has been withdrawn
by the manufacturers, because of links with mental dis-
orders
31 July 2008 Amended Odds ratios converted to risk ratios throughout
31 July 2008 Amended Converted to new review format.
6 August 2007 New citation required and conclusions have changed Substantive amendment
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Smoking Cessation; Amides [adverse effects; ∗therapeutic use]; Body Weight [drug effects]; Piperidines [adverse effects; ∗therapeutic
use]; Pyrazoles [adverse effects; ∗therapeutic use]; Pyridines [adverse effects; ∗therapeutic use]; Randomized Controlled Trials as Topic;
Receptor, Cannabinoid, CB1 [∗antagonists & inhibitors]; Secondary Prevention; Smoking [∗drug therapy]; Smoking Prevention
MeSH check words
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